The first step in effectively managing patients with copd involves correctly diagnosing the condition. COPD is defined as airflow limitation that is not fully reversible and must be confirmed by spirometry. As many as 73% of patients with COPD will have significant reversibility on at least one occasion with repeat bronchodilator testing.6 Most patients with COPD have a combination of emphysema (a pathological diagnosis consisting of destroyed alveoli) and chronic bronchitis (a clinical definition of a productive cough, in which sputum is produced on most days for at least 3 months in 2 consecutive years and other causes of chronic cough have been excluded). Many patients appear normal and do not complain of respiratory symptoms; therefore, many are not diagnosed until their disease is advanced.
A case that illustrates some of the issues with diagnosing COPD is that of a patient who was seen by us on the pulmonary consult service earlier this year. The patient was in the hospital with fever, cough, and shortness of breath for 2 weeks (as well as with multiple masses on chest radiographs that was ultimately found by bronchoscopy to be actinomycosis in her lungs). She was a long-time smoker (two packs per day for 32 years). During our interview and examination, she denied any problems with shortness of breath or cough until 2 weeks ago. On physical examination, however, we could barely hear her breath sounds, even though she was taking deep breaths, which suggested severe air trapping. We inquired further about her respiratory symptoms over the last couple of years. After probing, she admitted to having to slow down in her construction job due to “getting old” (she was 49) and eventually admitting to a “smoker’s cough” that produced one and one-half cups of sputum per day (even though she continued to deny that this was a “real cough”). Her spirometry revealed very severe obstruction to airflow (FEV1 of 16% of the predicted value). Patients like this one are examples of why it is important to ask about changes in activities over time. Patients often deny symptoms of dyspnea because they reduce their activity level to the point where they do not perceive shortness of breath.
All patients with COPD must undergo spirometry to diagnose the disease. By definition, all patients with COPD have an FEV1 to FVC ratio of less than 70%, but the severity of COPD is based on the FEV1 percent of the predicted value.7 The FEV1 does not consistently predict disability or mortality among patients with COPD, but it is useful for guiding therapy.7 Because smoking abstinence is the most effective way to reduce the age-related natural decline in lung function, all patients with COPD should receive smoking cessation counseling (active smokers) or reinforcement of the importance of remaining smoke free (former smokers).7 The influenza vaccine can reduce serious injury and death in patients with underlying respiratory conditions; therefore, it is also recommended for all patients with COPD.7,8 When respiratory complaints are present in patients with mild COPD (normal FEV1, but a low ratio), short-acting bronchodilators (ß2-agonists and anticholinergics: ipratropium bromide) should be prescribed as needed (not scheduled) to help reduce symptoms and improve exercise tolerance.7 These agents have not been shown to modify the clinical course, the rate of decline of the pulmonary function, or survival in patients with COPD, however.7,9-11
Patients with low FEV1 (<80% predicted) should receive scheduled therapy with one or more long-acting bronchodilators, in addition to the as-needed short-acting bronchodilator(s).7 In addition to the significant improvement in FEV1 that patients experience with these medications, these long-acting agents have been shown to improve quality of life and functional status and to reduce the number of acute exacerbations of COPD (AECOPD) by 22% to 26%.11 None of these medications are approved by the FDA for any of these indications, though; they are approved only for bronchodilation based on improvements in FEV1. Although the FDA has not approved the use of inhaled corticosteroids (ICS) as a single agent for patients with COPD, the guidelines state that these agents may be used in cases of frequent episodes of AECOPD in patients with severe and very severe disease (FEV1 <50% predicted).7 This recommendation is based on the combined results of several clinical trials suggesting a reduction of episodes of AECOPD in patients treated with ICS. These trials were not designed or powered to study AECOPD as a primary endpoint; therefore, the FDA does not consider this evidence conclusive enough to approve any of the ICS as a single agent for the management of COPD.
Long-acting agents that are approved by the FDA for bronchodilation in COPD
- a long-acting anticholinergic agent: tiotropium
- two long-acting ß2-agonists (LABA): salmeterol and formoterol
- a combination agent with a LABA and an inhaled corticosteroid: salmeterol plus fluticasone propionate (approved only for patients with COPD associated with chronic bronchitis)
In addition to medications, other strategies to improve outcomes are recommended for patients with COPD. Pulmonary rehabilitation programs improve health status, quality of life, and exercise tolerance but have not been shown to improve survival or reduce hospitalization rates in patients with COPD. The beneficial effects of these programs tend to fade over time unless patients continue to exercise and apply the techniques learned in the pulmonary rehabilitation program. According to the guidelines, pulmonary rehabilitation is recommended for all patients with moderate to very severe COPD (FEV1 <80% predicted).11,12 In addition, patients with very severe COPD (with FEV1 <30% predicted) should be screened for hypoxemia, because supplemental oxygen use for at least 18 hours per day has been convincingly demonstrated to improve mortality of COPD patients with chronic, resting hypoxemia.7,13,14 Potential surgical options for select patients with very severe COPD include lung-volume reduction surgery (LVRS) and lung transplantation. LVRS may be considered in carefully selected patients with heterogeneous lung disease (upper lobe bullae) who do not significantly improve with an intensive pulmonary rehabilitation program (low exercise capacity).15 Patients with COPD with certain characteristics might qualify for lung transplantation: poor quality of life due to an extremely limited functional status; sustained abstinence from smoking for at lest 6 months; and no significant comorbidities. It is important for clinicians and patients to understand that, although lung transplantation does not prolong life, it has the potential to significantly improve the quality of life for these patients.16
COPD has been characterized as a chronic inflammatory condition with multiple associated comorbid conditions associated with former tobacco use. For every smoker who dies from COPD, three others die from smoking-related cardiovascular disease, cancer, and other nonrespiratory-related conditions.17 Psychiatric effects of COPD have also been well studied, with documentation of anxiety, sleep disturbances, and depression.18 Patients with severe obstruction have a 2.5 times higher risk of depression than controls.19 Another common comorbidity in patients with COPD is osteoporosis, and the proportion of patients with osteoporosis increases with the severity of the obstruction.20 Studies have suggested that the presence of osteoporosis in patients with COPD has several causative factors, including corticosteroid use, low body mass index (BMI), malnutrition, smoking, and immobility. Furthermore, COPD itself may be a risk factor for osteoporosis.
Most of the management of patients with COPD occurs in the acute care setting, but to optimize the management of the disease, health care providers should change their focus from acute to chronic care models. Effective chronic care models involve the community and health system to develop an effective strategy to decrease the frequency of exacerbations and decrease resource utilization, thus improving outcomes for this patient population.21
Important facts about chronic obstructive pulmonary disease in the United States
- COPD is the fourth leading cause of death with mortality rates that are rising at an alarming rate.
- COPD is projected to be the third leading cause of death worldwide by the year 2020.
- COPD is the second leading cause of disability (behind heart disease).
- COPD is under-recognized, under-diagnosed, under-treated, and the number-one cause of referral for lung transplantation.1-5
One patient, who was a self-referral to our private outpatient pulmonary consultant clinic, was a 57-year-old male, former smoker with severe COPD (FEV1 of 46% predicted), who denied any other medical problems. He had experienced five episodes of AECOPD within the previous 6 months and was treated as an outpatient, and he had also been hospitalized three times within the previous year for AECOPD and/or pneumonia. His only medication was albuterol, which he used about 16 times per day. He was severely limited by his dyspnea and had to give up playing golf (which was his passion) about 9 months before. Upon further questioning and study, he was found to have a severe anxiety disorder and panic attacks associated with dyspnea and severe osteoporosis. He was treated with tiotropium and fluticasone/salmeterol combination inhalers, and he was encouraged to use his albuterol only when he experienced dyspnea (not scheduled). Additionally, he was started on buspirone and referred to a cognitive behavioral therapy program for his anxiety. He was also referred to a pulmonary rehabilitation program, started on a bisphosphonate for osteoporosis, and given an action plan to help manage early symptoms of acute exacerbation of COPD at home. Based on his personalized plan, this patient worked closely with a case manager, who taught him to recognize symptoms of AECOPD so that he could start treatment with an oral corticosteroid and an antibiotic if he experienced a sustained worsening of his symptoms for at least 48 hours. Within 2 months after his initial visit, he was back on the golf course and his quality of life had markedly improved. By the end of the first year, he had not required any hospitalizations and had experienced only two episodes of AECOPD, which were successfully treated at home according to his action plan. This patient’s primary care physician was focused on treating each acute exacerbation, but had not scheduled any appointments when the patient was not acutely ill to help address other issues, such as comorbidities and methods to prevent future episodes of AECOPD, which are critical to successfully managing this chronic illness.
COPD is associated with high cost, morbidity, and mortality but can be successfully managed. Because patients often deny symptoms of dyspnea, asking probing questions about changes in activity levels and symptoms over time in patients with risk factors for COPD is important to identify the disease earlier in its course. Spirometry is required for the diagnosis of COPD. The most important intervention for all patients with COPD is smoking cessation/abstinence, as this slows the rate of decline of FEV1 in this population. Vaccinations against influenza in addition to smoking cessation are important for all patients with COPD. Long-acting inhalers and pulmonary rehabilitation programs improve outcomes and are important for the chronic management of patients with COPD with an FEV1 <80% predicted. Chronic oxygen therapy (at least 18 hours per day) reduces mortality in COPD patients with resting hypoxemia.
In addition, as health care providers today, we should shift our priorities and our focus of care from the reactive, acute management of problems associated with COPD to the chronic care of comorbidities, emphasizing the prevention of complications of the disease. Finally, patients and health care providers should be encouraged and understand that this disease is absolutely treatable and many strategies are available to improve symptoms and quality of life and reduce the morbidity and mortality of COPD.
Sandra G. Adams, MD, MS (), is assistant professor; Juan Sanchez, MD, is a fellow, Department of Medicine, Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health Science Center at San Antonio and The South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division, San Antonio.
- Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ. 2002; 51:1-16.
- National Institutes of Health, National Heart, Lung, and Blood Institute. Morbidity and mortality: 2004 chartbook on cardiovascular, lung, and blood diseases. May 2004 [cited: December 2005]. Available at: [removed]www.nhlbi.nih.gov/resources/docs/04a_chtbk.pdf[/removed].
- Davis P, Lay-Yee R, Sinclair O, Gribben B. Maori/non-Maori patterns of contact, expressed morbidity and resource use in general practice: data from the Waikato Medical Care Survey 1991-2. N Z Med J. 1997;110:390-2.
- Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. [review]. Eur Respir J. 2006;27:188-207.
- Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report—2006. J Heart Lung Transplant. 2006;25:880-92.
- Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators [review]. Chest. 2004;126(2 suppl):125S-137S; discussion 159S-161S.
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
- Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community [see comment]. N Engl J Med. 1994; 331:778-84.
- Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-505.
- Rennard SI, Calverley P. Rescue! Therapy and the paradox of the Barcalounger. Eur Respir J. 2003;21:916-7.
- Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003; 290:2301-12.
- Ries AL. Position paper of the American Association of Cardiovascular and Pulmonary Rehabilitation. Scientific basis of pulmonary rehabilitation. J Cardiopulm Rehabil. 1990;10:418-41.
- Global Initiative for Chronic Obstructive Lung Disease. GOLD Teaching Slide Kit. [cited: November 1, 2004]. Available at: www.goldcopd.com.
- Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1:681-6.
- Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema [see comment]. N Engl J Med. 2003;348:2059-73.
- Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease [see comment]. Lancet. 1998;351:24-7.
- Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002; 51:300-3003.
- Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127:1205-11.
- van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax. 2002;57:412-6.
- Biskobing DM. COPD and osteoporosis [review]. Chest. 2002;121:609-20.
- Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med. 2007;167(6):551-61.